Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Jps Holding Sc


Published on

Executive Summary for JPSHoldinf SC presentation, products and projects

  • Login to see the comments

  • Be the first to like this

Jps Holding Sc

  1. 1. JPSHoldingSCServing Life SciencesIndustries Since 1993 Proprietary & Confidential;
  2. 2. Core Business Portfolio Management Products evaluation Products development Licensing-In and Out Expert Reports Regulatory dossiers development and submission: medicines, food supplements, dietary foods for special medical purposes. Drug Delivery Technology Proprietary & Confidential;
  3. 3. Licensing-in (for Clients) Paediatics drugs, medical food, food supplements BCAA Proprietary & Confidential;
  4. 4. Licensing-out AS 21: skin ulcers treatment (medical device) AS 22: mucitis treatment (medical device) Dualsetron®: Chemotherapy-Induced Nausea and Vomiting treatment (Internal) Biridone®: Bipolar disorders (Internal) Thixans® technology: thixotropic formulation Proprietary & Confidential;
  5. 5. MEDICAL For of skin injuries AS-21 Proprietary & Confidential; CE Authorization 0459
  6. 6. FIRST SPECIFIC TREATMENT AGAINST: Bedsore (Superficial & Deep) Superficial & Deep Skin Injuries Pressure sore/Pressure ulcers Decubitus ulcers Diabetic skin ulcers A NEW TRIPLE ACTION APPROACH Proprietary & Confidential;
  7. 7. SALES New product: CE marking in August 2010 2 Trial launch in Finland January 2010 Sales Finland (Aktisor): 32 000 Launched in Austria 2010 – 10 000 units Israel- February 2011 Planned: Egypt, Middle East countries, India, Irak, S. Africa, Australia, Proprietary & Confidential;
  8. 8. AS 22 Specific treatment forChemotherapy Induced oralmucositis (CIOM) Proprietary & Confidential;
  9. 9. AS 22 OROCHEM® Mucitis following hemo and radiotherapy Colorless, odorless, sweet, viscous, 100 natural solution. Easy to apply, no side effects. Registered as a Class IIa medical device due to its mechanical effects. Proprietary & Confidential;
  10. 10. Dualsetron® Fixed-Dosecombination for Chemotherapy-Induced Nausea And Vomiting treatment. Proprietary & Confidential;
  11. 11. Proprietary & Confidential;
  12. 12. Biridone® Bipolar-disorders treament Patented formulation for once-day- treatment Proprietary & Confidential;
  13. 13. Development Status:  CR formulation completed  Analytical development completed  Stability studies  Pilot Pk study completed  MBDD protocol completed Proprietary & Confidential;
  14. 14. THIXANS®: THE THIXOTROPIC DEVICE Pure or formulated active ingredient or microparticulate dosage forms (pellets, beadlets, spheroids etc..) manufactured by usual pharmaceutical technologies are embedded into a Thixotropic Cushion ® either extemporaneously or regenerated by the microparticule itself. Proprietary and Confidential: deNovelda Farmaceutica
  15. 15. Thixotropic Diffusion coating CoatingDrug Encapsulation TechnologiesMicrospheres Thixotropic Cushion® Proprietary and Confidential: deNovelda Farmaceutica